Baxalta to initiate clinical trial of BAX 826 in haemophilia A
20 November 2015 | By Victoria White
Baxalta expects to begin treating participants in the open-label, dose-finding study by early 2016...
List view / Grid view
News
EC grants marketing authorisation for cystic fibrosis drug Orkambi
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
Benepali receives positive opinion from CHMP
20 November 2015 | By Victoria White
Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel...
EC grants marketing authorisation to Kyprolis in multiple myeloma
20 November 2015 | By Victoria White
The announcement makes Kyprolis (carfilzomib) the first irreversible proteasome inhibitor approved in the EU for use in combination treatment of patients with relapsed multiple myeloma.
New data shows potential of ALS-008176 in RSV
19 November 2015 | By Victoria White
In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo...
Cancer Drugs Fund public consultation launched
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
Atopic dermatitis treatment market to more than double in value
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
NICE recommends Xofigo (radium-223) for prostate cancer
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
Phase III study to evaluate pemetrexed and pembrolizumab in NSCLC
19 November 2015 | By Victoria White
Lilly and Merck are to evaluate the safety and efficacy of the combination of pemetrexed and pembrolizumab in a Phase III study in non-squamous NSCLC...
Servier exercises options to acquire worldwide rights to UCART19
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
FDA approves Narcan Nasal Spray to treat opioid overdose
19 November 2015 | By Victoria White
Until this approval, naloxone was only approved in injectable forms, most commonly delivered by syringe or auto-injector...
New long-term data for Opdivo in advanced melanoma announced
19 November 2015 | By Victoria White
In the CheckMate -066 trial, Opdivo continued to demonstrate superior overall survival versus dacarbazine with 57.7% of patients alive at two years compared to 26.7% of patients treated with dacarbazine...
First patient enrolled in trial of amatuximab in mesothelioma
18 November 2015 | By Victoria White
Amatuximab is a monoclonal antibody (mAb) that triggers antibody-dependent cellular cytotoxicity against tumour cells expressing mesothelin...
ECDC survey shows increasing threat of antibiotic resistance
18 November 2015 | By Victoria White
Survey results released by the ECDC show that the situation continues to worsen with regard to the spread of CPE in the EU, with 3 countries reporting an endemic situation...
Pfizer’s Phase 3 Xalkori NSCLC trial meets primary objective
18 November 2015 | By Victoria White
Xalkori demonstrated significantly prolonged progression-free survival in previously untreated East Asian patients with ALK-positive advanced NSCLC...
